Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome
Launched by UNIVERSITY OF CHICAGO · Jan 26, 2008
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
The objective was to determine the effect of intranasal corticosteroid therapy on T-regulatory cells and other inflammatory cytokines in adenoid tissues in children with obstructive sleep apnea syndrome.Children were randomized to either no treatment or treatment with fluticasone furoate nasal spray, 55 μg/nostril daily, for 2 weeks before adenotonsillectomy. Adenoid tissue was obtained at the time of the procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age: between 2 and 12 years
- • Polysomnogram results showing AHI \>5/hr irrespective of saturations
- • No other significant medical problems except well controlled asthma
- • No chronic medication intake except bronchodilators and leukotriene receptor antagonists
- • No systemic steroids within the past month
- • No intranasal steroids within the past 2 weeks
- Exclusion Criteria:
- • Patients with OSAS who are overweight (BMI\>95th percentile for age) or who have neurological or craniofacial abnormalities as these tend to have OSAS related to these factors per se.
- • Females of the specified age group who have already had their first period.
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Fuad M Baroody, MD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials